SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC
Position in GH — Guardant Health, Inc.
CIK 1638555
Boston, MA
Position in GH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$145,183,580
+$65,476,122 QoQ
Shares Held
967,697
+12.1% QoQ
Ownership
0.721%
of shares outstanding
% of Portfolio
3.77%
of 13F equity value
Holder Rank
#39
of 594 holders
Holding Since
Mar 2020
8 quarters on record
Voting authority
Sole 72%
Shared 0%
None 28%
Common Shares in GH Over Time
Shares Held
Position Value (USD)
Derivatives in GH
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$32,329,500
PutShares
350,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $270,450,827 across 3 Diagnostics & Research names. GH ranks #1 (53.7% of the industry book) .
All Filings in GH
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $145,183,580 | 967,697 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $32,329,500 | 350,000 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $79,707,458 | 862,915 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $87,018,990 | 851,958 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $6,872,800 | 110,000 | Shares | Sole | 2025-11-14 | |
| 2020-12-31 | $10,250,084 | 79,532 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $8,921,944 | 79,817 | Shares | Sole | 2020-11-16 | |
| 2020-06-30 | $20,178,085 | 248,713 | Shares | Sole | 2020-08-14 | |
| 2020-03-31 | $13,391,944 | 192,413 | Shares | Sole | 2020-05-15 | |
| 2020-03-31 | $6,946,080 | 99,800 | Put | Sole | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||